Trifluridine-tipiracil (Lonsurf) for refractory metastatic colorectal cancer
Record ID 32016000797
Authors' recommendations: Description of Technology: This report focuses on the use of the trifluridine (TFD) and tipiracil hydrochloride (TPI) combination (Lonsurf; previously called TAS-102) for the treatment of refractory metastatic colorectal cancer (CRC). TFD is an antineoplastic thymidine-based nucleoside analog that acts as a nucleoside metabolic inhibitor, and TPI is a thymidine phosphorylase inhibitor. The combination agent is administered orally. Patient Population: TFD-TPI is used to treat adult patients with metastatic CRC who have been previously treated with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy, an anti-vascular endothelial growth factor (VEGF) biological therapy, and, if RAS (KRAS, HRAS, NRAS) wild-type, an anti-epidermal growth factor receptor (EGFR) therapy.
Project Status: Completed
Year Published: 2016
URL for published report: The report may be purchased from:http://www.hayesinc.com/hayes/crd/?crd=36446
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: United States
- Antineoplastic Combined Chemotherapy Protocols
- Colorectal Neoplasms
Organisation Name: HAYES, Inc.
Contact Address: 157 S. Broad Street, Suite 200, Lansdale, PA 19446, USA. Tel: 215 855 0615; Fax: 215 855 5218
Contact Name: firstname.lastname@example.org
Contact Email: email@example.com
Copyright: 2014 Winifred S. Hayes, Inc
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.